Beyond the Skin: Topical Amphotericin B Nanocarriers Targeting Cutaneous Leishmaniasis with Suppression of Lymphatic Parasite Burden.

ABSTRACT:

Background/objectives

Cutaneous leishmaniasis (CL) remains a global health challenge, with treatment options often limited by drug resistance and systemic toxicity. Amphotericin B (AmB) represents a promising alternative. but intravenous administration causes severe systemic adverse effects. Despite growing interest in topical therapies, knowledge gaps remain regarding the comparative efficacy of delivery systems, including the influence of treatment timing and potential intrinsic effects. This study aimed to develop and characterize different topical AmB formulations (polymeric nanoparticles (PCL-AmB), a lipid-based (Oil_AmB) formulation, and a gel emulsion) to evaluate their in vivo efficacy against CL in a murine model, considering treatment initiation timing and potential intri

SUBMITTER: Alexandrino-Junior F 

PROVIDER: S-EPMC12821423 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature